Symic Biomedical reports MODIFY2 phase II trial results of SB-061 for knee osteoarthritis Feb. 8, 2018
Silenseed initiates phase II study of siG12D LODER in locally advanced pancreatic cancer Feb. 8, 2018
YL Biologics reports successful completion of phase III trial of etanercept biosimilar YLB-113 Feb. 8, 2018
Sage Therapeutics' SAGE-217 given FDA breakthrough therapy designation for major depressive disorder Feb. 8, 2018
Case Western, Sangamo awarded grant to advance research on gene-edited T cells to treat HIV Feb. 8, 2018
RSS